Literature DB >> 22653369

Temperature- and time-dependent changes in TLR2-activated microglial NF-κB activity and concentrations of inflammatory and anti-inflammatory factors.

Tomohiro Matsui1, Moe Tasaki, Takahiro Yoshioka, Yukari Motoki, Hidehiro Tsuneoka, Junzo Nojima.   

Abstract

PURPOSE: Therapeutic hypothermia protects neurons following injury to the central nervous system (CNS). Microglia express toll-like receptors (TLRs) that play significant roles in pathological processes in sterile CNS injury. We have examined the effects of culture temperature on the TLR2-activated microglial production of cytokines and nitric oxide (NO), which are known to be associated with CNS damage, and the possible involvement of nuclear factor-κB (NF-κB) activation underlying such effects.
METHODS: Rat microglia were cultured with a selective TLR2 agonist, Pam(3)CSK(4), under hypothermic, normothermic, and hyperthermic conditions, and with Pam(3)CSK(4) in the presence of a NF-κB activation inhibitor at 37 °C. Cytokine and NO levels and NF-κB p65 activation were measured.
RESULTS: The production of tumor necrosis factor-alpha (TNF-α), interleukin-10 (IL-10), and NO and the activation of NF-κB p65 were reduced by hypothermia, but augmented by hyperthermia at 3-6, 24-48, 48, and 0.5 h, post-treatment initiation, respectively. Pharmacological inhibition of NF-κB activation impaired the Pam(3)CSK(4)-induced TNF-α, IL-10, and NO production.
CONCLUSIONS: In TLR2-activated microglia, hypothermia reduced, while hyperthermia increased, the early activation of NF-κB and the subsequent NF-κB-mediated production of TNF-α, IL-10, and NO in a time-dependent manner, suggesting that attenuation of these factors via suppression of NF-κB in microglia is one possible neuroprotective mechanism of therapeutic hypothermia. Moreover, temperature-dependent changes in microglial TNF-α production during the early phase and IL-10 and NO production during the late phase indicate that these factors might be useful as clinical markers to monitor hypothermia-related neuronal protection and hyperthermia-related neuronal injury.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22653369     DOI: 10.1007/s00134-012-2591-3

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  42 in total

1.  Neurochemical monitoring in the management of severe head-injured patients with hypothermia.

Authors:  S Yamaguchi; K Nakahara; T Miyagi; T Tokutomi; M Shigemori
Journal:  Neurol Res       Date:  2000-10       Impact factor: 2.448

2.  Nerve growth factor induces resistance of PC12 cells to nitric oxide cytotoxicity.

Authors:  K Wada; N Okada; T Yamamura; S Koizumi
Journal:  Neurochem Int       Date:  1996-11       Impact factor: 3.921

3.  Systemically administered interleukin-10 reduces tumor necrosis factor-alpha production and significantly improves functional recovery following traumatic spinal cord injury in rats.

Authors:  J R Bethea; H Nagashima; M C Acosta; C Briceno; F Gomez; A E Marcillo; K Loor; J Green; W D Dietrich
Journal:  J Neurotrauma       Date:  1999-10       Impact factor: 5.269

4.  Reduced cerebral ischemia-reperfusion injury in Toll-like receptor 4 deficient mice.

Authors:  Can-Xiang Cao; Qing-Wu Yang; Feng-Lin Lv; Jie Cui; Hua-Bin Fu; Jing-Zhou Wang
Journal:  Biochem Biophys Res Commun       Date:  2006-12-18       Impact factor: 3.575

5.  Mild hypothermia inhibits nuclear factor-kappaB translocation in experimental stroke.

Authors:  Hyung Soo Han; Murat Karabiyikoglu; Stephen Kelly; Raymond A Sobel; Midori A Yenari
Journal:  J Cereb Blood Flow Metab       Date:  2003-05       Impact factor: 6.200

6.  Toll-like receptor 2 mediates CNS injury in focal cerebral ischemia.

Authors:  Seija Lehnardt; Sabrina Lehmann; David Kaul; Katharina Tschimmel; Olaf Hoffmann; Sabine Cho; Christina Krueger; Robert Nitsch; Andreas Meisel; Joerg R Weber
Journal:  J Neuroimmunol       Date:  2007-09-12       Impact factor: 3.478

7.  Marked protection by moderate hypothermia after experimental traumatic brain injury.

Authors:  G L Clifton; J Y Jiang; B G Lyeth; L W Jenkins; R J Hamm; R L Hayes
Journal:  J Cereb Blood Flow Metab       Date:  1991-01       Impact factor: 6.200

8.  Induction of 70-kDa heat shock protein and hsp70 mRNA following transient focal cerebral ischemia in the rat.

Authors:  H Kinouchi; F R Sharp; M P Hill; J Koistinaho; S M Sagar; P H Chan
Journal:  J Cereb Blood Flow Metab       Date:  1993-01       Impact factor: 6.200

Review 9.  Toll-like receptors.

Authors:  Kiyoshi Takeda; Tsuneyasu Kaisho; Shizuo Akira
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

10.  TLR2 has a detrimental role in mouse transient focal cerebral ischemia.

Authors:  Gina Ziegler; Denise Harhausen; Claudia Schepers; Olaf Hoffmann; Christina Röhr; Vincent Prinz; Janett König; Hans Lehrach; Wilfried Nietfeld; George Trendelenburg
Journal:  Biochem Biophys Res Commun       Date:  2007-05-30       Impact factor: 3.575

View more
  4 in total

1.  Hypothermia at 35 °C reduces the time-dependent microglial production of pro-inflammatory and anti-inflammatory factors that mediate neuronal cell death.

Authors:  Tomohiro Matsui; Yusuke Yoshida; Masashi Yanagihara; Hiromi Suenaga
Journal:  Neurocrit Care       Date:  2014-04       Impact factor: 3.210

2.  Hypothermia Reduces but Hyperthermia Augments T Cell-Derived Release of Interleukin-17 and Granzyme B that Mediate Neuronal Cell Death.

Authors:  Tomohiro Matsui; Natsumi Kawahara; Arisa Kimoto; Yusuke Yoshida
Journal:  Neurocrit Care       Date:  2015-08       Impact factor: 3.210

3.  [Nle4, D-Phe7]-α-MSH Inhibits Toll-Like Receptor (TLR)2- and TLR4-Induced Microglial Activation and Promotes a M2-Like Phenotype.

Authors:  Lila Carniglia; Delia Ramírez; Daniela Durand; Julieta Saba; Carla Caruso; Mercedes Lasaga
Journal:  PLoS One       Date:  2016-06-30       Impact factor: 3.240

4.  Hypothermia reduces toll-like receptor 3-activated microglial interferon-β and nitric oxide production.

Authors:  Tomohiro Matsui; Yukari Motoki; Yusuke Yoshida
Journal:  Mediators Inflamm       Date:  2013-03-25       Impact factor: 4.711

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.